Orexigen Therapeutics has identified a possible path to approval for Contrave, its obesity drug. Approval could come as early as 2014 if things go smoothly. There have been no new prescription diet drugs introduced in the U.S. in more than a decade.

Orexigen Therapeutics has identified a possible path to approval for Contrave, its obesity drug. Approval could come as early as 2014 if things go smoothly. There have been no new prescription diet drugs introduced in the U.S. in more than a decade.

After months of uncertainty as it sought to resolve a dispute with the Food and Drug Administration, La Jolla-based Orexigen Therapeutics Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99